Case Report
Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance
Bibliographic Data
| ID | 15519842 |
|---|---|
| Authors | Kang Li (0000-0001-6218-5715, Third Affiliated Hospital of Sun Yat-sen University), Yingtao Liao (Sun Yat-sen University), Zhihua Yang (0009-0001-4134-872X, Sun Yat-sen University), Caishuang Yang (Sun Yat-sen University), Minhua Chen (0000-0003-0513-1301, Sun Yat-sen University), Xiuhua Wu (Sun Yat-sen University), Zhaoyu Gan (Sun Yat-sen University, corresponding author) |
| Year | 2021 |
| Volume | 11 |
| Pages | 529672-529672 |
| Publication date | 2021-01-08 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2020.529672 |
| PMID | 33488408 |
| OpenAlex | W3119409514 |
| Language | EN |
| References cited | 5 |
Background: Medication non-adherence is prevalent in patients with bipolar disorder (BD). Long-acting injectable antipsychotics (LAIAs) are widely used to improve compliance with treatment. This study aimed to illustrate the effectiveness, compliance, and safety profile of once-monthly paliperidone palmitate (PP1M), a novel therapeutic LAIA, in the management of bipolar I disorder (BDI). Method: A prospective follow-up was arranged to 11 BDI patients who were prescribed PP1M as monotherapy or adjunctive treatment. Severity of symptoms, disturbing behavior, status of employment, 17-item Hamilton Depression Rating Scale (HAMD-17), and Young Mania Rating Scale (YMRS) were evaluated at the baseline and the endpoint of follow-up. Clinical Global Impression-Bipolar Disorder-Severity of Illness Scale (CGI-BP) and Treatment Emergent Symptom Scale (TESS) were measured at each injection of PP1M. Compliance, relapse or switch, and new hospitalization were monitored through the period of follow-up. Results: The median duration of treatment was 14 months, ranging from 5 to 22 months. The scores (mean ± standard deviation) of HAMD-17, YMRS, and CGI-BP generally decreased from the baseline (16.1 ± 10.3, 30.9 ± 12.6, 5.3 ± 0.7) to the endpoint (7.4 ± 5.7, 3.7 ± 3.2, 2.3 ± 0.7). No disturbing behavior was detected at the endpoint. Neither new hospitalization nor manic/mixed episode occurred during treatment, whereas mild to moderate depressive episodes were reported in three cases. The status of employment of 10 participants (90.9%) was improved, and no new safety concern was detected. Conclusion: PP1M might offer a new valid treatment option in the long-term management of BDI, especially for those with poor compliance with oral medication. However, more studies are needed to further justify such role
Adjunctive treatment · Antipsychotic · Bipolar disorder · Bipolar I disorder · Clinical endpoint · Clinical Global Impression · Clinical trial · Lithium (medication · Mania · Paliperidone · Paliperidone Palmitate · Psychiatry · Rating scale · Schizophrenia (object-oriented programming · Young Mania Rating Scale · Bipolar Disorder and Treatment · Electroconvulsive Therapy Studies · Medicine · Psychology · Schizophrenia research and treatment · Internal Medicine
Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative
Canadian Network for Mood and Anxiety Treatments ( Canmat ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder
A Rating Scale for Mania
A Rating Scale for Depression
Music-instruction intervention for treatment of post-traumatic stress disorder
| Citation velocity | historical |
|---|---|
| Highly cited | No |